Biotech’s On The Rise Says Leading Expert

Toxicity testing of new compounds is critical for the drug development process. If you aren’t a trained expert in biotech, you may not be familiar with his process. A 28-day repeated-dose toxicity study uses the test drug on mammals to observe the effects of the test drug. This testing reveals whether or not there are toxic effects of the investigational product candidate and determines the extent of side effects the drug could produce. The completion of a successful 28-day repeated-dose toxicity study is the next step toward identifying a safe, starting dose to be administered to humans and fight disease.


More good news was released last month concerning PPCH, the Australian-based biotechnology company seeking to develop new long term treatments for cancer. Propanc announced the completion of the low dose group for the GLP-Compliant 28-day repeat-dose toxicity study for its lead product PRP, a solution for once daily intravenous administration of pancreatic proenzymes trypsinogen and chymotrypsinogen.

This is a crucial stage for testing new drugs as this stage tests the drug for both safety and efficacy. “We are very pleased to have successfully completed the first stage of our 28-day study,” said James Nathanielsz, Propanc’s Chief Executive Officer. “There were no clinical observations, nor any adverse effects observed from any of the animals and, in fact, all animals gained body weight within the expected range.”


No treatment related effects were observed in the animals in the study and the once-daily dosing by IV injection was successfully accomplished. Results from the study help provide a rationale for a safe starting dose for first-in-man studies targeted late 2017, or early 2018, depending on successful completion of manufacture of the investigational new drug (IND).

“Given we have now identified a dosing group in the 28-day study with no safety concerns, it gives us great confidence that we are close to defining a safe starting dose for our First-In-Man studies,” said Professor Klaus Kutz, Propanc’s Chief Medical Officer.


Vascular Biogenics Ltd. (VLBT) is also in the business of curing cancer! The technology driving their platform is a proprietary tissue- and condition-specific regulatory element (“promoter”) that is activated only in angiogenic, proliferating endothelial cells of blood vessels.

Xoma Corp’s (XOMA) scientific research produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. Two of the assets were developed through the XOMA Metabolic or XMet platform, which consists of separate classes of Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of metabolic disorders.

Cara Therapeutics (CARA) is a clinical-stage biotech company working on a novel drug for pain as opioid addiction is increasing. CARA is aiming to produce a pain drug that doesn’t have the side effects of today’s opioid analgesics, including the euphoria that can lead to drug abuse.

INSYS Therapeutics (INSYS) is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. They recently announced bringing a new drug onto the market to help alleviate nausea and vomiting for AIDS patients with anorexia associated weight loss.

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.

For Full Legal Disclaimer Click Here.

Media Contact
Company Name: Microcap Speculators
Contact Person: Media Manager
Phone: 1-702-720-6310
Country: United States